All In Biotech

Drug Trial Radar · NCT07877038

Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function

A Study to Evaluate the Pharmacokinetic Characteristics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Hepatic Impairment and in Those With Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Apr 7, 2027

Study completion Apr 7, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized study to assess how DA-302168S is absorbed, distributed, metabolized, and eliminated after a single oral dose. The study includes three groups: subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), and healthy subjects matched by gender, age, and body mass index (BMI). It will also explore the relationship between baseline liver function measures and the pharmacokinetic (PK) parameters of DA-302168S, to support appropriate dosing recommendations for patients with liver impairment.

Conditions

  • Obesity, Overweight
  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • DA-302168SDrug

    Small molecule GLP-1RA tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax) of DA-302168STime frame: Predose up to 72 hours postdose (D1 to D4)
  2. Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168STime frame: Predose up to 72 hours postdose (D1 to D4)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.